Although Congress was able to pass a $1.2 trillion bipartisan infrastructure package last week, the nearly $1.8 trillion Build Back Better bill remains bogged down by infighting among Democrats. Its numerous drug pricing provisions will likely undergo changes prior to any votes.
For now, the bill contains a limited drug price negotiation provision for the Medicare program, as well as a $35 monthly cap on out-of-pocket costs (or 25% of the negotiated price) for individuals who require insulin. The bill also would require manufacturers to pay the government rebates on certain drugs reimbursed by Medicare Parts B and D if a drug’s price rises faster than the rate of inflation.
Although Congress was able to pass a $1.2 trillion bipartisan infrastructure package last week, the nearly $1.8 trillion Build Back Better bill remains bogged down by infighting among Democrats.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
